Microbiome - Competitive Landscape, Technology and Pipeline Analysis, 2017

  • ID: 4330605
  • Drug Pipelines
  • 280 Pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 5
Global Microbiome Pipeline Scenario, Products and Associated Companies

Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2016 provides comprehensive insights about pipeline drugs across this microbiome based products.

This report provides information on the therapeutic development based on the Microbiome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

There are total 73 drugs in pipeline out of which 2 products is in Phase II/III, 8 products in Phase II, 6 product are in Phase I, 1 product are in Phase 0 and 1 Product in IND. Around 34 products are in Pre-clinical, 18 products are in Discovery stage of development and 3 products is in Unknown stage of development. Companies have also gone in collaboration with different partners.

The market of microbiome therapies is progressing rapidly. Various companies are getting on the action, aiming to target microbes to treat various types of diseases. Synlogic is currently developing 6 drugs that address disease by targeting gut microbiome using their synthetic biotics approach. The company is also collaborated with different partners to apply their platform to create innovative synthetic biotics for the treatment of major diseases in disease areas including inflammation, metabolism, oncology and CNS. All products of Synlogic are in Pre-Clinical and Discovery stage. Other companies are also in race for developing the products that target the microbes. Seres therapeutics is also developing the 5 products with their lead program, SER-109 for the prevention of recurrent Clostridium difficile infections, which has granted the Breakthrough therapy by FDA.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

To ensure the report is updated with the latest information, this report may take up to 24 hours to be delivered after purchase.

Reports Highlights:

  • Microbiome Pipeline scenario
  • Collaborations & partnering deals
  • Current Prominent Research Areas and Key Players
  • Pipeline product profiles Microbiome Technologies and Targeted Antigens
  • Licensing opportunities
  • Market Drivers and Barriers

Scope:

  • Overview of the global Microbiome pipeline scenario, products and associated companies information
  • Coverage of global Microbiome under development
  • Competitive landscape of products for key players and related indications
  • Coverage of licensors, collaborators and Development partners, deal terms and deal values estimation
  • Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
  • Highlights of licensing & collaboration opportunities and funding details
  • Highlights of latest Microbiome technologies and innovative companies

Please Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated therapy.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

1. Executive Summary

2. Executive Summary Snapshot

3. Microbiome Overview

  • Microbiome - Host Interaction
  • Human Microbiota Ecosystems
  • Role of Microbiota in Health and Disease
  • Effects of Probiotics and Prebiotics on gut microbiota
  • Microbiome Projects under development
  • Future of Microbiome
  • Hinderances for Microbiome as therapy
  • Challenges in studying the microbiome
  • Unmet needs of Microbiome

4. Pipeline Products Analysis

  • Microbiome - Number of Products (N) and Stages of Development with Therapy Area
  • Microbiome Analysis by Therapy Area and Companies
  • Collaboration with Institutes
  • Number of Collaboration with Companies Year Wise
  • Number of Collaboration with Institutes Year wise
  • Collaboration with Companies
  • Collaboration with Institutes/Universities
  • Technology
  • Designation
  • Financing

5. Pipeline Therapeutics

  • Therapeutics under Development by Companies
  • Mid Stage Products (Phase II)
  • Comparative Analysis
  • Early Stage Products (Phase I and IND)
  • Comparative Analysis
  • Discovery and Pre-clinical stage Products
  • Comparative Analysis

6. Drug 1

  • Product Description
  • Research and Development
  • Product Development Activities

7. Drug 2

  • Product Description
  • Research and Development
  • Product Development Activities

8. Therapeutic Assessment

  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

9. Companies Planning for Future Development in Microbiome

10. Appendix

11. Consulting Services

12. About the Publisher

13. Contact Us

14. Disclaimer

List of Tables
Table 1: Collaboration with Companies, 2017
Table 2:Collaboration with Institutes/Universities, 2017
Table 3: Microbiome technologies, 2017
Table 4: Designation, 2017
Table 5: Grants, 2017
Table 6: Financing, 2017
Table 7: Number of Products Under Development for Microbiome, 2017
Table 8: Number of Products under Development by Companies, 2017
Table 9: Mid Stage Products (Phase II), 2017
Table 10: Early Stage Products (Phase I and IND), 2017
Table 11: Discovery and Pre-clinical Stage Products, 2017
Table 12: Number of Products Under Development for Microbiome, 2017
Table 13: Assessment by Combination Products, 2017
Table 14: Assessment by Route Of Administration, 2017
Table 15: Assessment by Stage and Route Of Administration, 2017
Table 16: Assessment by Molecule Type, 2017
Table 17: Assessment by Stage and Molecule Type, 2017

List of Figures
Figure 1: Microbiome - Number of Products (N) and with Therapy Area, 2017
Figure 2: Number of Collaborations with Institute and Company, 2017
Figure 3: Number of Collaboration of Company, 2017
Figure 4: Number of Collaboration of Institute, 2017
Figure 5: Microbiome, number products and technology, 2017
Figure 6: Number of products and designation, 2017
Figure 7: Designation and year, 2017
Figure 8: Grants, 2017
Figure 9: Financing, 2017
Figure 10: Financing, 2017
Figure 11: Number of Products under Development for Microbiome, 2017
Figure 12: Mid Stage Products (Phase II), 2017
Figure 13: Early Stage Products (Phase I and IND), 2017
Figure 14: Discovery and Pre-clinical Stage Products, 2017
Figure 15: Assessment by Monotherapy Products, 2017
Figure 16: Assessment Combination Products, 2017
Figure 17: Assessment by Route of Administration, 2017
Figure 18: Assessment by Stage and Route of Administration, 2017
Figure 19: Assessment by Molecule Type, 2017
Figure 20:Assessment by Stage and Molecule Type, 2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Seres Therapeutics
  • Synlogic
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll